MetaCap

Black Diamond Therapeutics Inc. (BDTX)

NASDAQ: BDTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

1.31-0.08 (-5.76%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BDTX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$75.28M
EPS (TTM)
-$0.77
52-week range
1.31 – 3.97
Day range
1.31 – 1.41
Volume / Avg
663.19K / 697.70K
Beta
—

52-week range

$1.31$3.97

BDTX stock today

Shares of Black Diamond Therapeutics (BDTX) finished lower on Nov 20 at $1.31, a drop of 5.76% or $0.08 per share, versus the S&P 500's 3.70% decline. At this level, BDTX sits near the bottom of its 52-week range of $1.31 to $3.97: 67.0% below the high, set on May 20, 2026 and 0.0% above the low. BDTX is down 46.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 65.5%.

Black Diamond Therapeutics has posted a net loss over the last twelve months (EPS of -$0.77), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Black Diamond Therapeutics

Company profile

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Mark A. Velleca M.D., Ph.D.
Headquarters
Cambridge, MA
Employees
21
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Black Diamond Therapeutics generated $70.0 million in revenue, up 0.0% from fiscal 2024. Net income was $22.4 million, for a net margin of 32.0%. Operating margin was 17.9%.

Black Diamond Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$70.00M$0———
Growth—————
Net income$22.37M$-69.68M$-82.44M$-91.17M$-125.60M
EPS (diluted)$0.39$-1.27$-1.88$-2.52$-3.47

Analyst forecast

Forecast

Consensus (8 analysts)

none

Avg. price target

$10.00+663.36%

  • Strong buy 2
  • Buy 5
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $8.00High $14.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.17 vs $-0.03
Surprise
-466.67%

BDTX news

All BDTX news

Black Diamond Therapeutics peers

Health Care sector
BDTX peer companies
CompanyPrice% ChgMarket capCompare
CRDFCardiff Oncology Inc.0.8528-4.46%$66.34Mvs BDTX
TNYATenaya Therapeutics Inc.0.2866-3.99%$65.32Mvs BDTX
ATRAAtara Biotherapeutics Inc.6.33-0.16%$64.49Mvs BDTX
NMRANeumora Therapeutics Inc.0.3339-3.78%$63.01Mvs BDTX
ZURAZura Bio Limited Class A0.9305-2.30%$89.63Mvs BDTX
CSBRChampions Oncology Inc.4.34-1.36%$60.41Mvs BDTX
LENZLENZ Therapeutics Inc.2.97-11.23%$93.16Mvs BDTX
CHRSCoherus Oncology Inc.0.3698-4.47%$57.15Mvs BDTX

Indexes, lists and sector

Black Diamond Therapeutics stock FAQ

What is Black Diamond Therapeutics's stock price today?

BDTX last traded at $1.31 as of Nov 20, 4:00 PM EST, down 5.76% on the day. Prices are delayed at least 15 minutes.

Who is Black Diamond Therapeutics's CEO?

Dr. Mark A. Velleca M.D., Ph.D. is the chief executive officer of Black Diamond Therapeutics Inc., which has about 21 employees.

What is the BDTX 52-week high?

The 52-week high for BDTX is $3.97 and the 52-week low is $1.31. The stock is currently 67.0% below its high.

Compare BDTX